Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NY › Cooperstown › NPI 1780600577
Hospital

Mary Imogene Bassett Hospital

Mary Imogene Bassett Hospital was paid $121.76M by Medicaid between Jan 2018 and Dec 2024, across 545 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 18% of everything it billed.

33Billing provider infoMARY IMOGENE BASSETT HOSPITAL
COOPERSTOWN, NY 13326
33aNPI1780600577assigned 07/14/2006
33bProvider typeRural Acute Care Hospital
28Total paid$121.76M
24GClaims1,853,705
24DCodes billed545
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Rural Acute Care Hospital providers in New York

Rank by total paid#1 of 7
Median peer was paid$13.87M
This provider vs. median8.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,431$28K
2019108,351$5.94M
2020307,845$17.19M
2021383,329$21.67M
2022379,257$33.80M
2023380,072$25.58M
2024incomplete293,420$17.56M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 18% 156,914 140,506 $21.99M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 15% 134,785 122,018 $18.52M
G9005 Coordinated care fee, risk adjusted maintenance 9.6% 38,415 38,415 $11.69M
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis 4.0% 34,298 32,622 $4.86M
80053 Comprehensive metabolic panel 2.0% 47,467 43,584 $2.45M
Q3014 Telehealth originating site facility fee 2.0% 42,203 35,326 $2.44M
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) 1.7% 14,296 14,105 $2.09M
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) 1.6% 13,353 13,342 $2.00M
90832 Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient 1.6% 15,699 10,336 $1.95M
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 1.5% 14,541 13,836 $1.86M
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) 1.5% 11,543 10,741 $1.77M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.4% 23,907 22,997 $1.72M
533 more codes
45380 Colonoscopy, flexible; with biopsy, single or multiple 1.3% 1,495 $1.62M
90834 Psychotherapy session, about 45 minutes 1.2% 9,397 $1.44M
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 1.1% 1,844 $1.39M
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years 1.1% 9,401 $1.31M
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) 1.1% 8,936 $1.29M
99283 Emergency room visit (moderate) 1.0% 6,681 $1.27M
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 2,405 $1.21M
99285 Emergency room visit (most serious) <1% 6,805 $1.19M
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 8,238 $1.14M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 24,807 $1.13M
81025 <1% 14,812 $1.08M
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 11,819 $1.02M
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 2,523 $950K
96127 <1% 28,067 $935K
99284 Emergency room visit (serious) <1% 4,292 $777K
20610 <1% 2,880 $756K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 666 $700K
80048 Basic metabolic panel (calcium, ionized) <1% 13,313 $647K
90686 <1% 26,833 $636K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 21,469 $595K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 773 $580K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 4,218 $566K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 3,710 $536K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 17,088 $523K
80061 Lipid panel <1% 27,534 $517K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 12,599 $514K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 9,779 $474K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 10,377 $470K
59025 Fetal non-stress test <1% 2,686 $453K
77067 Screening mammography, bilateral, including computer-aided detection <1% 6,209 $442K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 1,829 $438K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 6,511 $412K
70450 Computed tomography, head or brain; without contrast material <1% 1,066 $411K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 8,674 $410K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 55,667 $401K
17110 <1% 1,487 $400K
86850 <1% 4,362 $362K
96361 Intravenous infusion, hydration; each additional hour <1% 1,715 $353K
84443 Thyroid stimulating hormone (TSH) <1% 33,202 $343K
90791 Psychiatric diagnostic evaluation <1% 1,485 $295K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 1,433 $284K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 537 $280K
87507 <1% 1,153 $276K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 5,947 $274K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 11,911 $271K
36416 <1% 3,083 $261K
36415 Collection of venous blood by venipuncture <1% 39,087 $259K
77063 Screening digital breast tomosynthesis, bilateral <1% 5,732 $249K
90792 Psychiatric diagnostic evaluation with medical services <1% 977 $246K
90651 <1% 5,536 $231K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 4,608 $229K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 2,698 $228K
90715 <1% 8,407 $221K
76830 Ultrasound, transvaginal <1% 2,137 $214K
93017 <1% 1,115 $206K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 12,218 $206K
J1050 Injection, medroxyprogesterone acetate, 1 mg <1% 3,471 $202K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,949 $202K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,966 $201K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 287 $199K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 7,971 $198K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 317 $194K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 9,766 $193K
96375 Therapeutic injection; each additional sequential IV push <1% 4,628 $192K
78815 Positron emission tomography (PET) for limited area imaging <1% 259 $190K
52000 <1% 103 $189K
80051 <1% 4,763 $183K
J9271 Injection, pembrolizumab, 1 mg <1% 16 $181K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 5,491 $174K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 16,420 $173K
71046 Radiologic examination, chest; 2 views <1% 5,136 $169K
J7298 Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg <1% 182 $169K
76770 <1% 866 $161K
92012 Ophthalmological services: medical examination and evaluation, intermediate, established patient <1% 2,537 $158K
90670 <1% 7,355 $157K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 916 $148K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 237 $147K
73630 <1% 3,347 $147K
90648 <1% 6,803 $139K
73564 <1% 2,341 $139K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 895 $138K
73610 <1% 2,613 $137K
93971 <1% 983 $128K
83036 Hemoglobin; glycosylated (A1C) <1% 22,088 $125K
90677 <1% 2,889 $124K
76801 <1% 1,078 $122K
94010 <1% 1,294 $122K
92557 <1% 2,681 $119K
76536 <1% 1,088 $117K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 528 $115K
90680 <1% 5,739 $112K
92567 <1% 3,393 $104K
90700 <1% 4,555 $103K
G0378 Hospital observation service, per hour <1% 2,217 $103K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 894 $103K
99385 <1% 811 $103K
72110 <1% 1,435 $103K
97162 <1% 933 $102K
87634 <1% 3,949 $99K
90633 <1% 4,724 $99K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 2,116 $97K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 163 $97K
82607 <1% 9,777 $96K
87081 <1% 14,451 $92K
99406 <1% 3,489 $92K
71271 <1% 291 $91K
64493 <1% 63 $90K
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries <1% 336 $89K
77336 <1% 259 $89K
90723 <1% 4,801 $89K
86901 <1% 4,417 $89K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 4,303 $88K
92134 <1% 1,552 $86K
83655 <1% 7,245 $85K
51798 <1% 312 $84K
73030 <1% 2,035 $82K
82728 <1% 7,932 $81K
84439 <1% 9,722 $78K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 4,019 $76K
87481 <1% 1,824 $75K
85027 <1% 13,026 $74K
71275 Computed tomographic angiography, chest, with contrast material <1% 149 $73K
73110 <1% 1,736 $73K
95004 Percutaneous tests with allergenic extracts, immediate type reaction <1% 216 $73K
86900 <1% 4,421 $73K
90734 <1% 3,229 $70K
73130 <1% 1,161 $70K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 365 $70K
87086 Culture, bacterial; quantitative colony count, urine <1% 13,693 $70K
88304 <1% 2,142 $70K
83970 <1% 1,762 $69K
99188 <1% 1,106 $68K
11104 <1% 134 $67K
71045 Radiologic examination, chest; single view <1% 2,935 $66K
76642 <1% 630 $65K
80076 <1% 2,086 $64K
36591 <1% 1,889 $64K
86803 <1% 6,273 $64K
96367 <1% 845 $63K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 2,193 $60K
82565 <1% 7,938 $60K
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient <1% 1,585 $59K
D9997 <1% 1,190 $59K
90710 <1% 2,843 $59K
J1756 Injection, iron sucrose, 1 mg <1% 1,067 $58K
Q9992 Injection, buprenorphine extended-release (sublocade), greater than 100 mg <1% 26 $57K
90750 <1% 410 $56K
96160 <1% 1,263 $56K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 158 $54K
90707 <1% 2,336 $53K
A9585 Injection, gadobutrol, 0.1 ml <1% 2,518 $53K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 30,200 $50K
90619 <1% 1,750 $50K
85610 <1% 7,333 $49K
91322 <1% 611 $49K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 134 $49K
83735 <1% 12,056 $48K
93226 <1% 272 $48K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 5,451 $47K
81003 <1% 20,668 $47K
90716 <1% 2,137 $46K
99443 <1% 495 $46K
90732 <1% 952 $45K
86580 <1% 3,003 $45K
V2020 Frames, purchases <1% 1,472 $45K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 760 $44K
G0444 Annual depression screening, 5 to 15 minutes <1% 1,148 $44K
G9001 Coordinated care fee, initial rate <1% 580 $44K
84450 <1% 6,647 $42K
87522 Neg quan hep c or qual rna <1% 1,122 $42K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 5,232 $42K
73502 <1% 853 $41K
88112 <1% 212 $41K
90837 Psychotherapy session, about an hour <1% 306 $41K
81001 <1% 8,767 $41K
87077 <1% 5,406 $40K
90697 <1% 1,759 $40K
84466 <1% 5,716 $39K
99442 <1% 417 $39K
95117 <1% 569 $39K
84460 <1% 5,103 $39K
90656 <1% 1,987 $39K
0001A <1% 1,070 $39K
A4649 Surgical supply; miscellaneous <1% 1,472 $37K
83690 <1% 6,438 $35K
83880 <1% 1,134 $35K
95909 <1% 188 $35K
86140 <1% 5,961 $34K
69209 <1% 631 $34K
84484 <1% 3,460 $34K
82746 <1% 3,295 $33K
97161 <1% 328 $33K
82570 <1% 6,631 $32K
84702 <1% 3,216 $31K
0002A <1% 818 $31K
11720 <1% 801 $31K
92133 <1% 560 $30K
43235 <1% 41 $29K
93922 <1% 382 $29K
96415 <1% 76 $29K
69210 <1% 426 $29K
58300 <1% 208 $29K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 83 $28K
73140 <1% 590 $28K
0071A <1% 772 $28K
99381 <1% 167 $28K
86618 <1% 4,212 $28K
73080 <1% 659 $27K
74018 <1% 862 $27K
92587 <1% 586 $27K
83540 <1% 7,079 $26K
84520 <1% 6,171 $26K
95886 <1% 502 $26K
84480 <1% 3,215 $26K
82043 <1% 5,634 $25K
42820 Tonsillectomy and adenoidectomy; younger than age 12 <1% 12 $25K
87070 <1% 5,148 $25K
82948 <1% 5,459 $25K
87653 <1% 493 $25K
87340 <1% 3,591 $24K
58100 <1% 53 $24K
0072A <1% 653 $24K
96523 <1% 475 $23K
99383 <1% 177 $23K
J2469 Injection, palonosetron hcl, 25 mcg <1% 1,378 $23K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,255 $23K
99386 <1% 185 $23K
71250 <1% 41 $22K
82330 <1% 1,954 $22K
84403 <1% 1,549 $22K
90620 <1% 709 $22K
87186 <1% 4,545 $22K
92083 <1% 344 $21K
84153 <1% 2,613 $21K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 633 $21K
70551 Magnetic resonance imaging, brain; without contrast material <1% 51 $20K
54150 <1% 25 $20K
81513 <1% 1,850 $20K
82040 <1% 3,207 $20K
G0447 Face-to-face behavioral counseling for obesity, 15 minutes <1% 203 $19K
86780 <1% 2,760 $19K
82378 <1% 1,296 $19K
94729 <1% 527 $18K
17000 <1% 85 $18K
G0297 Low dose ct scan (ldct) for lung cancer screening <1% 69 $18K
93242 <1% 121 $18K
90747 <1% 253 $18K
99441 <1% 151 $18K
85652 <1% 6,167 $18K
64721 <1% 13 $17K
82947 <1% 3,656 $17K
86762 <1% 2,103 $17K
88307 <1% 163 $17K
86666 <1% 3,789 $17K
72050 <1% 338 $17K
0124A <1% 484 $16K
96376 <1% 1,228 $16K
0054A <1% 427 $16K
0064A <1% 433 $16K
90480 <1% 613 $15K
11102 <1% 30 $15K
95908 <1% 107 $15K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 136 $14K
D0120 Dental checkup, returning patient <1% 340 $14K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 249 $14K
J2704 Injection, propofol, 10 mg <1% 9,943 $14K
86480 <1% 241 $13K
84402 <1% 1,119 $13K
92579 <1% 398 $13K
90472 Immunization administration, each additional vaccine (list separately) <1% 6,425 $13K
90713 <1% 468 $12K
73590 <1% 245 $12K
84146 <1% 970 $12K
83001 <1% 778 $12K
87205 <1% 2,690 $12K
V2103 Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens <1% 374 $12K
99384 <1% 88 $11K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 926 $11K
82784 <1% 1,547 $11K
96417 <1% 471 $11K
72170 <1% 363 $11K
0134A <1% 298 $11K
0051A <1% 289 $10K
31575 <1% 227 $10K
88342 <1% 135 $10K
87468 <1% 370 $10K
85018 <1% 5,332 $10K
80306 <1% 2,114 $10K
82247 <1% 2,540 $10K
83516 <1% 1,484 $10K
86753 <1% 2,139 $10K
0004A <1% 274 $10K
97035 <1% 456 $10K
85379 <1% 986 $9K
11056 <1% 38 $9K
82248 <1% 1,127 $9K
87476 <1% 468 $9K
92551 <1% 168 $9K
90746 <1% 360 $9K
82950 <1% 1,747 $9K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 270 $9K
99382 <1% 69 $9K
86706 <1% 1,241 $8K
J7120 Ringers lactate infusion, up to 1000 cc <1% 10,277 $8K
86787 <1% 1,723 $8K
84550 <1% 1,860 $8K
97535 Self-care/home management training, each 15 minutes <1% 231 $8K
11721 <1% 136 $8K
86003 <1% 395 $8K
83615 <1% 2,490 $8K
73090 <1% 231 $8K
95816 <1% 39 $8K
92552 <1% 186 $8K
88720 <1% 1,774 $8K
83520 <1% 1,012 $8K
85014 <1% 917 $7K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 4,937 $7K
90696 <1% 397 $7K
86769 <1% 271 $7K
59430 <1% 730 $7K
84100 <1% 2,104 $7K
82550 <1% 1,307 $7K
27096 <1% 12 $7K
J3490 Unclassified drugs <1% 329 $7K
90847 Family psychotherapy with the patient present, 50 minutes <1% 38 $7K
86431 <1% 1,525 $6K
20550 <1% 27 $6K
77334 <1% 13 $6K
87469 <1% 371 $6K
87478 <1% 370 $6K
92250 <1% 93 $6K
94726 <1% 38 $6K
86704 <1% 924 $6K
72125 Computed tomography, cervical spine; without contrast material <1% 27 $6K
73562 <1% 98 $6K
82150 <1% 1,301 $6K
87484 <1% 370 $6K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 29 $6K
84132 <1% 1,798 $6K
82533 <1% 395 $6K
29075 <1% 29 $6K
86038 <1% 1,467 $6K
86308 <1% 657 $6K
D1110 Prophylaxis - adult <1% 83 $6K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 36 $6K
82310 <1% 1,927 $6K
85730 <1% 1,448 $6K
0052A <1% 144 $5K
77300 <1% 18 $5K
J0690 Injection, cefazolin sodium, 500 mg <1% 2,334 $5K
25600 <1% 12 $5K
C1713 Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) <1% 25 $5K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 8,217 $5K
84155 <1% 2,017 $5K
10060 <1% 13 $5K
86376 <1% 635 $5K
87040 <1% 581 $4K
0011A <1% 119 $4K
83605 <1% 1,243 $4K
86617 <1% 596 $4K
C1769 Guide wire <1% 252 $4K
A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose <1% 292 $4K
83721 <1% 1,123 $4K
G0296 Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) <1% 30 $4K
77073 <1% 79 $4K
84425 <1% 444 $3K
90662 <1% 477 $3K
83550 <1% 1,215 $3K
90632 <1% 111 $3K
G0127 Trimming of dystrophic nails, any number <1% 89 $3K
0031A <1% 112 $3K
84156 <1% 979 $3K
93246 <1% 26 $3K
J7030 Infusion, normal saline solution , 1000 cc <1% 6,920 $3K
84075 <1% 1,252 $3K
87807 <1% 611 $3K
86235 <1% 303 $3K
80347 <1% 3,691 $3K
C1898 Lead, pacemaker, other than transvenous vdd single pass <1% 54 $3K
J1453 Injection, fosaprepitant, 1 mg <1% 67 $3K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 6,803 $3K
90647 <1% 101 $3K
83993 <1% 155 $3K
0081A <1% 89 $3K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 5,611 $3K
C9290 Injection, bupivacaine liposome, 1 mg <1% 39 $2K
80326 <1% 3,690 $2K
86592 <1% 955 $2K
81329 <1% 55 $2K
80364 <1% 3,690 $2K
86765 <1% 326 $2K
11055 <1% 14 $2K
0154A <1% 80 $2K
77065 Tomosynthesis, mammo <1% 24 $2K
83002 <1% 164 $2K
C1760 Closure device, vascular (implantable/insertable) <1% 73 $2K
86800 <1% 364 $2K
82105 <1% 512 $2K
D0150 Comprehensive oral evaluation - new or established patient <1% 56 $2K
82670 <1% 133 $2K
58301 <1% 24 $2K
86364 <1% 381 $2K
0082A <1% 63 $2K
81596 <1% 71 $2K
86039 <1% 619 $2K
86665 <1% 298 $2K
J2795 Injection, ropivacaine hydrochloride, 1 mg <1% 1,801 $2K
97116 <1% 49 $2K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 4,910 $2K
93880 <1% 12 $2K
87493 <1% 197 $2K
99407 <1% 68 $2K
82274 <1% 368 $2K
81511 <1% 39 $2K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 7,279 $2K
76882 <1% 29 $2K
94761 <1% 282 $2K
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose <1% 39 $2K
92341 <1% 25 $2K
67028 Intravitreal injection of a pharmacologic agent <1% 12 $2K
72082 <1% 25 $1K
90685 <1% 76 $1K
J7050 Infusion, normal saline solution, 250 cc <1% 2,661 $1K
84165 <1% 557 $1K
82977 <1% 275 $1K
80164 <1% 118 $1K
90381 <1% 53 $1K
C1887 Catheter, guiding (may include infusion/perfusion capability) <1% 91 $1K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 2,972 $1K
D1206 Topical application of fluoride varnish <1% 42 $1K
85045 <1% 393 $1K
J0689 Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg <1% 921 $1K
11200 <1% 16 $1K
86200 <1% 204 $1K
84160 <1% 558 $1K
J1030 Injection, methylprednisolone acetate, 40 mg <1% 345 $1K
J2785 Injection, regadenoson, 0.1 mg <1% 38 $1K
G0008 Administration of influenza virus vaccine <1% 256 $982.79
86870 <1% 15 $973.53
86708 <1% 102 $970.21
86664 <1% 165 $896.46
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 23 $890.52
90744 <1% 43 $800.07
92340 Fitting of spectacles, except for aphakia; monofocal <1% 13 $799.11
72100 <1% 15 $762.90
J3475 Injection, magnesium sulfate, per 500 mg <1% 1,009 $756.74
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 5,417 $744.41
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg <1% 2,200 $696.11
80349 <1% 1,289 $688.83
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,362 $638.48
87529 <1% 19 $628.25
86225 <1% 166 $623.17
J1170 Injection, hydromorphone, up to 4 mg <1% 1,684 $613.95
80178 <1% 81 $607.16
0083A <1% 18 $596.68
96411 <1% 19 $587.07
80377 <1% 1,879 $554.48
0012A <1% 14 $491.95
73660 <1% 13 $488.10
86735 <1% 95 $470.38
J1644 Injection, heparin sodium, per 1000 units <1% 1,138 $468.82
91321 <1% 49 $455.61
0074A <1% 23 $452.01
G0379 Direct admission of patient for hospital observation care <1% 25 $433.82
J7042 5% dextrose/normal saline (500 ml = 1 unit) <1% 884 $431.89
0053A <1% 12 $420.45
V2784 Lens, polycarbonate or equal, any index, per lens <1% 49 $396.35
J2371 Injection, phenylephrine hydrochloride, 20 micrograms <1% 555 $337.45
J2543 Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) <1% 34 $316.51
J2370 Injection, phenylephrine hcl, up to 1 ml <1% 1,118 $314.86
J1010 Injection, methylprednisolone acetate, 1 mg <1% 139 $313.75
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 937 $313.47
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 797 $305.02
88142 <1% 12 $295.76
87625 <1% 95 $292.74
92555 <1% 13 $286.00
17003 <1% 12 $281.07
86160 <1% 20 $274.20
64494 <1% 12 $262.74
86300 <1% 30 $245.70
J7060 5% dextrose/water (500 ml = 1 unit) <1% 832 $245.28
88302 <1% 19 $241.15
87075 <1% 26 $222.43
71101 <1% 12 $201.95
84481 <1% 25 $199.37
80329 <1% 772 $181.14
82272 <1% 66 $178.58
83883 <1% 22 $170.80
82374 <1% 88 $159.61
80177 <1% 24 $157.45
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,129 $155.61
J1650 Injection, enoxaparin sodium, 10 mg <1% 712 $140.96
J1598 Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg <1% 227 $136.71
84590 <1% 25 $131.22
84597 <1% 13 $128.12
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg <1% 158 $120.98
96380 <1% 16 $120.90
84295 <1% 28 $117.53
81015 <1% 99 $115.04
87102 <1% 28 $111.63
J1643 Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units <1% 96 $107.21
84446 <1% 13 $96.82
J1596 Injection, glycopyrrolate, 0.1 mg <1% 148 $95.99
80320 <1% 1,051 $89.94
A9270 Non-covered item or service <1% 348 $77.75
84630 <1% 13 $75.00
84202 <1% 12 $72.72
86696 <1% 12 $57.59
86255 <1% 16 $55.18
J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg <1% 14 $54.66
86695 <1% 12 $48.85
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 304 $46.04
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 84 $45.26
82465 <1% 16 $39.23
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 53 $38.50
J1171 Injection, hydromorphone, 0.1 mg <1% 36 $33.48
J0736 Injection, clindamycin phosphate, 300 mg <1% 22 $25.42
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg <1% 14 $15.81
82435 <1% 25 $14.66
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 353 $14.52
J2004 Injection, lidocaine hcl with epinephrine, 1 mg <1% 88 $12.71
94664 <1% 66 $12.40
87210 <1% 12 $10.89
J0737 Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg <1% 15 $9.61
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 27 $8.37
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 46 $5.58
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 37 $2.48
J2550 Injection, promethazine hcl, up to 50 mg <1% 14 $2.17
99495 0% 24 $0.00
92002 0% 12 $0.00
80323 0% 29 $0.00
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 0% 51 $0.00
99203 Doctor's office visit, new patient (routine) 0% 17 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSWINKO, PAUL (BASSETT MEDICAL CENTER VP)